INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $23,226 | +45.2% | 2,100 | +110.6% | 0.00% | +100.0% |
Q1 2022 | $16,000 | -61.0% | 997 | -61.2% | 0.00% | -66.7% |
Q4 2021 | $41,000 | +4000.0% | 2,568 | +4569.1% | 0.00% | – |
Q1 2021 | $1,000 | -98.0% | 55 | -97.2% | 0.00% | -100.0% |
Q4 2020 | $49,000 | -25.8% | 1,996 | +25.1% | 0.01% | -37.5% |
Q3 2020 | $66,000 | +842.9% | 1,596 | +903.8% | 0.01% | +700.0% |
Q2 2020 | $7,000 | -30.0% | 159 | -4.8% | 0.00% | -85.7% |
Q1 2020 | $10,000 | -33.3% | 167 | +29.5% | 0.01% | +600.0% |
Q4 2019 | $15,000 | +114.3% | 129 | +21.7% | 0.00% | 0.0% |
Q3 2019 | $7,000 | 0.0% | 106 | +6.0% | 0.00% | 0.0% |
Q2 2019 | $7,000 | -93.3% | 100 | -88.5% | 0.00% | -90.0% |
Q2 2017 | $104,000 | -38.8% | 867 | -42.6% | 0.01% | -44.4% |
Q1 2017 | $170,000 | +58.9% | 1,510 | +80.8% | 0.02% | +5.9% |
Q1 2016 | $107,000 | -61.5% | 835 | -55.2% | 0.02% | -64.6% |
Q4 2015 | $278,000 | +768.8% | 1,863 | +1763.0% | 0.05% | +500.0% |
Q1 2014 | $32,000 | – | 100 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |